Bristol Myers Squibb ($BMY) is a leading global biopharmaceutical company with a strong presence in oncology, hematology, immunology, cardiovascular, and neuroscience. As a major player in the pharmaceutical industry, Bristol Myers faces intense competition from other large, research-driven drug manufacturers, as well as from smaller biotech firms and generic drug producers. Understanding its competitive landscape is crucial for investors, partners, and industry observers.
Key Competitors and Peers of Bristol Myers Squibb
- AbbVie Inc. ($ABBV) – Competes directly in immunology and oncology, with strong product lines in both areas and significant exposure to biosimilar/generic pressure.
- Pfizer Inc. ($PFE) – Overlaps with Bristol Myers in Eliquis (co-commercialized), immunology, oncology, and biosimilars, operating in highly competitive and regulated markets.
- Amgen Inc. ($AMGN) – Provides explicit product-vs-product competition, especially in immunology and hematology, with direct overlap in several key drugs.
- Merck & Co., Inc. ($MRK) – Major competitor in immuno-oncology (Keytruda vs. Opdivo), with additional collaboration and licensing relationships.
- Johnson & Johnson ($JNJ) – Competes in oncology and immunology, with a broad pharmaceutical and medtech portfolio.
- Eli Lilly & Co. ($LLY) – Competes in oncology, immunology, and neuroscience, with overlapping products in immunology.
- Gilead Sciences Inc. ($GILD) – Competes at the portfolio level, especially in oncology and virology, though with less direct product overlap.
Competitive Peer Table
| Ticker | Company Name | Subsector | Market Cap |
|---|---|---|---|
| $BMY | Bristol Myers Squibb Co. | Drug Manufacturers - General | $122.78B |
| $ABBV | AbbVie Inc. | Drug Manufacturers - General | $406.87B |
| $PFE | Pfizer Inc. | Drug Manufacturers - General | $153.81B |
| $AMGN | Amgen Inc. | Drug Manufacturers - General | $199.20B |
| $MRK | Merck & Co., Inc. | Drug Manufacturers - General | $286.28B |
| $JNJ | Johnson & Johnson | Drug Manufacturers - General | $579.34B |
| $LLY | Eli Lilly & Co. | Drug Manufacturers - General | $884.72B |
| $GILD | Gilead Sciences Inc. | Drug Manufacturers - General | $178.71B |
Bristol Myers vs. Key Competitors
- Bristol Myers vs. AbbVie
Both companies are strong in immunology and oncology. AbbVie’s immunology products (Skyrizi, Rinvoq, Humira) compete with Bristol Myers’ Orencia and Sotyktu. Oncology competition is also significant, with AbbVie’s Venclexta and Elahere facing BMS’s hematology and oncology portfolio. AbbVie also has a large aesthetics and neuroscience business, which is less of a focus for BMS.
- Bristol Myers vs. Pfizer
Pfizer and BMS co-commercialize Eliquis, making them both partners and competitors. Both have significant immunology and oncology portfolios, and Pfizer’s broad biopharma business includes vaccines and biosimilars, areas where BMS is less active.
- Bristol Myers vs. Amgen
Amgen provides the clearest direct product competition, with Sotyktu (BMS) vs. Otezla (Amgen), Orencia (BMS) vs. Enbrel (Amgen), and Pomalyst/Imnovid and Revlimid (BMS) vs. Kyprolis (Amgen). Both face biosimilar and generic pressures.
- Bristol Myers vs. Merck
The most direct competition is in immuno-oncology, with Merck’s Keytruda and BMS’s Opdivo being leading checkpoint inhibitors. Merck and BMS also collaborate on Reblozyl and Winrevair, with BMS as the principal on sales.
- Bristol Myers vs. Johnson & Johnson
J&J’s broad portfolio overlaps with BMS in oncology and immunology. J&J’s Tremfya competes in the same category as BMS’s Sotyktu. J&J also has a significant medtech segment, which BMS does not.
- Bristol Myers vs. Eli Lilly
Lilly competes with BMS in oncology, immunology, and neuroscience. Taltz (Lilly) competes with Otezla (Amgen) and Sotyktu (BMS). Lilly’s focus on cardiometabolic health and neuroscience is broader than BMS’s.
- Bristol Myers vs. Gilead Sciences
Gilead’s competition with BMS is more at the portfolio level, especially in oncology and virology. Gilead’s strength in HIV and liver disease is less directly competitive with BMS’s core areas.
Conclusion
Bristol Myers Squibb ($BMY) operates in a highly competitive pharmaceutical landscape, facing formidable rivals across its key therapeutic areas. Its main competitors—AbbVie, Pfizer, Amgen, Merck, Johnson & Johnson, Eli Lilly, and Gilead Sciences—each bring unique strengths and overlapping product lines, particularly in oncology and immunology. While BMS maintains a robust growth and legacy portfolio, ongoing innovation and strategic positioning will be essential to maintain and grow its market share in the face of such strong competition.